Compumedics Limited stock analysis
Want to see AU:CMP full AI Analyst Report?
Compumedics Limited (CMP) Share Price & Analysis
CMP Stock Chart & Stats
- Day’s Range
- AUD 0.25 - AUD 0.25
- 52-Week Range
- AUD 0.22 - AUD 0.45
- Previous Close
- AUD 0.24
- Volume
- N/A
- Average Volume (3M)
- 39.51K
- Market Cap
- AUD 48.94M
- Enterprise Value
- AUD 59.50M
- Total Cash (Recent Filing)
- AUD 6.15M
- Total Debt (Recent Filing)
- AUD 14.11M
- Price to Earnings (P/E)
- 213.6
- Beta
- 0.88
- Next Earnings
- Mar 04, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth
The sustained increase in revenue indicates expanding demand for Compumedics’ sleep and neurological monitoring systems. Continued top-line growth can improve operating leverage, support investment in product development, and strengthen the company’s ability to build scale across healthcare markets.
Resilient Gross Margin
A resilient gross margin provides evidence that the company’s products retain meaningful economic value as revenue scales. Maintaining this level of gross profitability can support reinvestment, absorb some cost pressure, and provide a foundation for improving operating earnings over time.
Improved Free Cash Flow
The strong 2026 cash generation materially improves financial flexibility and shows that recent operations converted into cash rather than only reported revenue. If sustained, positive free cash flow can fund investment, reduce reliance on external financing, and strengthen resilience through the next several quarters.
Bears Say
Thin Profitability
Very thin profitability leaves little room for operational setbacks to affect earnings or cash generation. Although revenue is growing, modest changes in costs or demand could materially reduce net income, limiting internal funding capacity and making consistent earnings improvement an important execution requirement.
Profitability Volatility
The pronounced swings in profitability show that growth has not yet translated into dependable earnings power. This volatility makes results harder to forecast, reduces confidence in sustainable margins, and indicates that the business remains sensitive to execution and operating conditions over the medium term.
Low Return On Equity
A very low and recently negative return on equity indicates that the capital base is producing limited shareholder earnings despite the company’s revenue scale. Unless returns improve, Compumedics may struggle to compound equity value efficiently and may have less capacity to fund growth from retained profits.
Compumedics Limited News
Compumedics appoints adviser for Somfit US consumer program
Compumedics Limited ( ($AU:CMP) ) has shared an update. Compumedics Limited is a global medical device company developing, manufacturing and commercialising diagnostic technologies for sleep, brain and ultrasonic blood-flow monitoring.
CMP FAQ
What was Compumedics Limited’s price range in the past 12 months?
What is Compumedics Limited’s market cap?
When is Compumedics Limited’s upcoming earnings report date?
How were Compumedics Limited’s earnings last quarter?
Is Compumedics Limited overvalued?
Does Compumedics Limited pay dividends?
What is Compumedics Limited’s EPS estimate?
How many shares outstanding does Compumedics Limited have?
What happened to Compumedics Limited’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Compumedics Limited?
What is the TipRanks Smart Score and how is it calculated?
Compumedics Limited Stock Smart Score
Company Description
Compumedics Limited
Compumedics Limited is a global medical technology enterprise engaged in the full lifecycle of designing, producing, marketing, and distributing advanced diagnostic medical devices. Its market reach extends across Australia, the Asia Pacific region, the Americas, Europe, and the Middle East. The company's product portfolio is primarily focused on solutions for sleep and neurological disorders. For sleep diagnostics, offerings include sophisticated PSG:EEG amplification systems like the Grael 4K, portable recording units such as the Somté PSG and Siesta 802, wearable monitoring devices like Somfit/Somfit Pro, and transcutaneous monitors (e.g., TCM5 FLEX). In the field of neurology, Compumedics supplies devices like the ONsight A.V.S. for home ambulatory studies, a variety of EEG amplifiers (e.g., Grael 4K-EEG, Grael LT EEG), comprehensive long-term EEG monitoring systems (Neuvo 64-512 Channel LTM), and specialized EMG/EP systems (including Xegis Forte and Xegis G:NEO). Complementing its hardware, the company develops an extensive range of software, featuring the Profusion Sleep and EEG platforms, Profusion neXus 360 (a web-based system for patient data and lab management), a Multi-Modal Neuroimaging Suite, and workflow optimization tools like Profusion neXus Laboratory Management and Scheduler. Other software offerings include HD Digital Video integration and various specialized applications. Furthermore, Compumedics provides magnetoencephalography systems, cutting-edge brain research technologies, services for pharmaceutical clinical trials and research, as well as a diverse array of accessories and consumables crucial for diagnostic and research endeavors. Established in 1987, Compumedics Limited is based in Abbotsford, Australia, and functions as a subsidiary of D & DJ Burton Holdings Pty Ltd.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- David Burton
- Employees
- 175
- Website
- www.compumedics.com.au
- Address
- 30-40 Flockhart Street, Abbotsford, VIC, 3067, AU
Compumedics Limited (CMP) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 8 | 6 | 8 |
| Technical Analysis | 3 | 6 | 1 |
| Moving Averages | 5 | 0 | 7 |








